Table 4.
Diabetic Retinopathy course through the 38-months of follow-up.
| T2DM Patients + DR (n = 129) | T2DM Patients − DR (n = 158) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DR Impairment: 22% | DR Impairment: 27% | ||||||||||
| Mild | Moderate | Severe | Mild | Moderate | Severe | ||||||
| 13% | 5% | 4% | 12% | 9% | 5% | ||||||
| +A/ω3 | −A/ω3 | +A/ω3 | −A/ω3 | +A/ω3 | −A/ω3 | +A/ω3 | −A/ω3 | +A/ω3 | −A/ω3 | +A/ω3 | −A/ω3 |
| 3% | 10% | 2% | 3% | 1% | 3% | 3% | 9% | 2% | 7% | 2% | 3% |
T2DM: Type 2 diabetes mellitus; CG: Control group; +DR: With diabetic retinopathy; −DR: Without diabetic retinopathy; +A/ω3: Participants randomly assigned to the daily supplementation with antioxidants and omega 3 fatty acids; −A/ω3: No assigned to the supplementation regimen. Values are the percentages of DR impairment regarding the NDPR (non-diabetic retinopathy) clinical form. NDPR has been classified according to the ETDRS (early treatment diabetic retinopathy study) system [28] as a mild, moderate, or severe stage.